Biologicals

Influenza

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines containing the pandemic influenza A H1N1 (2009) virus: Update

H1N1 specific-update of TRS 941, Annex 5

Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Recommendations for the production and control of influenza vaccine (inactivated)

WHO Technical Report Series, No. 927, 2005, Annex 3

Influenza vaccine, live

Title: Requirements for Influenza Vaccine (Live); Adopted 1978, TRS No 638, Annex 3

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



NEW PUBLICATIONS

UPCOMING EVENTS


  • WHO Informal Consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products including biosimilars, Seoul, Republic of Korea, 27-28 April 2017
  • Working Group meeting on revision of WHO TRS 941, Annex 5: WHO biosafety risk assessment and Guidelines for the production and quality control of human influenza pandemic vaccines, Geneva, Switzerland, 9-10 May 2017
  • Working group meeting on Hepatitis E Vaccine, Geneva, Switzerland, 11-12 May 2017

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971